Eiger BioPharmaceuticals 2018-03-13T10:47:27+00:00

IN THE NEWS

Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to “All-Oral” Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress™ 2018

April 17th, 2018|

Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to “All-Oral” Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress™ 2018 PALO ALTO, Calif., April 17, 2018 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced additional positive lonafarnib (LNF) data from the LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program presented at The International Liver Congress™ 2018, in Paris, France.  A subanalysis of the LOWR-2 study reveals high response rates to LNF [...]

Eiger BioPharmaceuticals to Participate in Conferences in April

April 2nd, 2018|

Eiger BioPharmaceuticals to Participate in Conferences in April PALO ALTO, Calif. – April 2, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that Eiger will participate at upcoming investor, scientific, and orphan drug conferences in April. C. Wainwright Global Life Science Conference at Le Meridien in Monte Carlo, Monaco. Eiger will present a corporate overview and business update on April 9, 3:50 pm – 4:15 pm CET.  Eiger [...]

Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia

March 26th, 2018|

Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia PALO ALTO, Calif., March 26, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced the first patient dosed in PREVENT, a Phase 2, multi-center study of subcutaneous (SC) exendin 9-39 in post-bariatric surgical patients who experience dangerously low, postprandial blood glucose levels (hypoglycemia) known as post-bariatric hypoglycemia (PBH).  PREVENT will target [...]